Stereotactic Radiosurgery and Stereotactic Fractionated Radiotherapy in the Management of Brain Metastases
Department of Radiation Oncology, UNIL-CHUV, Rue du Bugnon 46, 1011 Lausanne, Switzerland
*
Authors to whom correspondence should be addressed.
Cancers 2024, 16(6), 1093; https://doi.org/10.3390/cancers16061093
Submission received: 23 January 2024
/
Revised: 21 February 2024
/
Accepted: 28 February 2024
/
Published: 8 March 2024
(This article belongs to the Special Issue Stereotactic Radiotherapy in Tumor Ablation)
Simple Summary
The management of brain metastases (BM) is a major issue in cancer treatment, and one of the main goals of BM treatment is to achieve effective disease control while concurrently preserving neurocognition and quality of life. Stereotactic radiosurgery (SRS) and radiation therapy (SRT) represent a mainstay option that is undergoing a significant paradigm evolution with unexpected opportunities and challenges. This review highlights the evidence and the emerging role of SRS-SRT in patients diagnosed with intact intracranial metastases.
Abstract
The management of brain metastases (BM) remains an important and complex issue in the treatment of cancer-related neurological complications. BM are particularly common in patients diagnosed with lung, melanoma, or breast cancer. Over the past decade, therapeutic approaches for the majority of BM patients have changed. Considering and addressing the fact that patients with BM are living longer, the need to provide effective local control while preserving quality of life and neurocognition is fundamental. Over the past decade, SRS and SRT have become a more commonly chosen treatment option for BM. Despite significant advances in the treatment of BM, numerous questions remain regarding patient selection and optimal treatment sequencing. Clinical trials are critical to advancing our understanding of BM, especially as more therapeutic alternatives become available. Therefore, it is imperative for interdisciplinary teams to improve their understanding of the latest advances in SRS-SRT. This review aims to comprehensively explore SRS and SRT as treatments for BM, covering clinical considerations in their application (e.g., patient selection and eligibility), managing limited and multiple intact BM, addressing brainstem metastases, exploring combination therapies with systemic treatments, and considering the health economic perspective.
